title: Practical approach to non-alcoholic fatty liver disease in patients with diabetes.
abstract: The prevalence of Type 2 diabetes is expected to increase in parallel with obesity rates and the ageing population. Recent studies show that Type 2 diabetes is associated with a twofold increase in the risk of non-alcoholic fatty liver disease, a leading cause of chronic liver disease. Individuals with non-alcoholic steatohepatitis, a more advanced stage of non-alcoholic fatty liver disease, are specifically at risk of developing fibrosis/cirrhosis (end-stage liver disease) and hepatocellular carcinoma; therefore, identifying individuals (with Type 2 diabetes) who are likely to develop hepatic complications is paramount. In the present clinical review, we discuss the potential impact of non-alcoholic fatty liver disease diagnosis on Type 2 diabetes, and the putative risk factors for developing non-alcoholic steatohepatitis and non-alcoholic steatohepatitis fibrosis. We highlight the limitations of currently used tools in non-alcoholic fatty liver disease diagnosis and staging, and provide an insight into future developments in the field. We present an example of a non-alcoholic fatty liver disease screening protocol and discuss the therapeutic options currently available to our patients.
authors: The Liver Unit, Barts Health NHS Trust, London, UK.
authors: F W D
authors: FW
authors: Tai
authors: The Liver Unit, Barts Health NHS Trust, London, UK.|Regeneration and Repair Group, Institute of Hepatology, London, UK.
authors: W-K
authors: WK
authors: Syn
authors: The Liver Unit, Barts Health NHS Trust, London, UK.|The Blizard Institute, Queen Mary, University of London, London, UK.
authors: W
authors: W
authors: Alazawi
mesh_terms: D015415:Biomarkers / Q000378:metabolism; D003924:Diabetes Mellitus, Type 2 / Q000150:complications* / Q000188:drug therapy; D004032:Diet; D000069196:Gastrointestinal Microbiome / Q000502:physiology; D006505:Hepatitis / Q000503:physiopathology; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D008049:Lipase / Q000235:genetics; D008103:Liver Cirrhosis / Q000175:diagnosis / Q000209:etiology; D008565:Membrane Proteins / Q000235:genetics; D065626:Non-alcoholic Fatty Liver Disease / Q000175:diagnosis / Q000209:etiology* / Q000628:therapy; D009765:Obesity / Q000150:complications; D011110:Polymorphism, Genetic / Q000235:genetics; D012307:Risk Factors; D040242:Risk Reduction Behavior; D016896:Treatment Outcome; D015431:Weight Loss / Q000502:physiology; D000217:Acyltransferases; D054512:Phospholipases A2, Calcium-Independent
chemical_list: D015415:Biomarkers; D007004:Hypoglycemic Agents; D008049:Lipase; D008565:Membrane Proteins; C533682:PNPLA3 protein, human; D000217:Acyltransferases; D054512:Phospholipases A2, Calcium-Independent